TL;DR
- 1.Two genetic variables (GHR Exon 3 deletion and IGF-1 promoter methylation) explain 43% of why growth peptide results differ between users on the same dose.
- 2.About 20% of people carry two full-length GHR copies (fl/fl), producing the weakest natural growth hormone receptor response. Dose escalation barely helps them.
- 3.A separate category of non-responders has loss-of-function variants in the ghrelin receptor (GHSR), meaning ipamorelin and MK-677 cannot even trigger GH release effectively.
- 4.d3-GHR carriers (roughly 50% of the population) show about 56% higher IGF-1 elevation from the same GH signal. High-responders should track bloodwork, not just feel.
- 5.A four-week baseline-plus-post IGF-1 blood test is the fastest practical screen for which bottleneck you have before changing your protocol.
In a 2025 study published in the Journal of Pediatric Endocrinology and Metabolism, 132 children were given identical doses of recombinant growth hormone. The researchers then tracked IGF-1 response. What they found would surprise most people running a growth peptide protocol: IGF-1 changes ranged across nearly 8 standard deviations, from far below baseline to far above. Same clinic. Same drug. Same dose. A prediction model incorporating 38 genetic variants across 18 genes explained 95.7% of that variation.
The share of IGF-1 response variation explained by just two factors: the GHR Exon 3 deletion and IGF-1 promoter methylation status, per a 2015 study in Endocrine Connections. Two variables. Nearly half the picture.
Growth peptides (ipamorelin, CJC-1295, GHRP-6, MK-677) work by triggering your pituitary to release growth hormone. That GH then signals your liver to produce IGF-1. The step-by-step cascade sounds simple. But three genetic bottlenecks sit between the peptide dose and the IGF-1 result, and any one of them can blunt the entire chain.
Think of it as a relay race with three handoffs. The peptide fires the starting gun (hitting the ghrelin receptor). GH carries the baton to the liver (binding the GH receptor). The liver hands IGF-1 to your muscle and fat cells (binding the IGF-1 receptor). A slow runner at any leg tanks the result, regardless of how strong the other two runners are.
Bottleneck 1: Can the peptide even trigger GH release?
Ipamorelin, MK-677, GHRP-6, and GHRP-2 are all ghrelin-mimetics. They work by binding to the ghrelin receptor, also called GHSR (growth hormone secretagogue receptor). GHSR then signals the pituitary to release a GH pulse. If your GHSR has a loss-of-function variant, this trigger step is partially or completely broken.
A 2024 paper in a pharmacogenomics journal identified 10 distinct GHSR loss-of-function variants, six of which were novel. Carriers showed partial to complete blunting of ghrelin-mimetic signaling, independent of pituitary health. Their pituitary cells could still release GH via other pathways. But ipamorelin and MK-677 could not pull the trigger effectively.
This is the "well, actually" correction most non-responders never hear. When ipamorelin does not work, the common advice is: raise the dose, check your source, add CJC-1295. The actual answer for GHSR-variant carriers is different: none of the ghrelin-mimetic peptides will work well for them, regardless of dose or quality. CJC-1295 works through a different receptor (GHRH receptor), so it is unaffected by GHSR variants. Switching to CJC-1295 alone or GHRH-based approaches is the correct protocol adjustment for this group.
Bottleneck 2: Does GH get converted to IGF-1 efficiently?
Once a GH pulse is released, it travels to your liver and binds the growth hormone receptor (GHR). How efficiently that receptor converts the GH signal into IGF-1 production depends largely on which version of GHR you carry.
The growth hormone receptor gene normally includes a region called exon 3. About 50% of people carry at least one copy of a natural deletion that removes this region, producing a slightly shorter receptor protein called d3-GHR. The deletion was first characterized in a 2004 paper in the Proceedings of the National Academy of Sciences (Dos Santos et al.). What followed was a decade of GH therapy trials establishing how large the effect was.
"d3-GHR carriers showed approximately 56% higher IGF-1 elevation in response to growth hormone stimulation compared to individuals with two full-length receptor copies. The d3 genotype, combined with chronological age, explained 24% of IGF-1 response variability in the pediatric GH challenge cohort."
Lopes et al., European Journal of Endocrinology, 2007
A 2023 review in Frontiers in Endocrinology (PMC10531306) synthesized the accumulated data: the d3-GHR isoform transmits GH signals roughly 30% more efficiently than the full-length receptor, primarily by enhancing STAT5B activation. STAT5B is the key transcription factor that carries the GH signal from the receptor to the nucleus, where it turns on IGF-1 gene expression. More efficient STAT5B activation means more IGF-1 produced per GH pulse.
What this means for your protocol
Two GH receptor architectures dominate the population. d3-GHR carriers (roughly 80% of people in most ancestry groups carry at least one copy) produce more IGF-1 per unit of GH. fl/fl carriers (roughly 20% of people, with variation by ancestry) run the lower-efficiency baseline.
For fl/fl carriers, the response to ipamorelin or CJC-1295 is real but muted. Dose escalation provides marginal additional benefit because the bottleneck is at the receptor, not at the peptide dose. Pulse frequency is the better lever. Three daily doses instead of two produces more total GH pulses hitting the receptor over 24 hours, which partially compensates for the per-pulse efficiency gap.
Bottleneck 3: Do your cells respond to the IGF-1 that gets produced?
Even when IGF-1 is produced in normal quantities, it still has to bind to IGF-1 receptors on your muscle cells, fat cells, and connective tissue to do anything useful. Two additional genetic variables shape this final step.
IGF1R (the cell-level receiver)
The IGF-1 receptor gene (IGF1R) has a well-characterized variant (rs2229765, sometimes labeled Arg1310His) that reduces receptor sensitivity. His/His carriers can have entirely normal circulating IGF-1 and still see blunted effects at the tissue level. A study of elderly Italian men (the TRELONG cohort) found A/A homozygotes had plasma IGF-1 levels 35% lower than G/G carriers at the same age, suggesting the His allele may reduce the efficiency of the entire GH-IGF axis over time. This explains why some users see bloodwork showing a normal IGF-1 spike but feel little effect in practice.
IGFBP-3 (how long IGF-1 stays active)
About 80% of circulating IGF-1 travels bound to IGFBP-3, a binding protein that extends IGF-1 half-life from minutes to hours. A promoter variant in the IGFBP3 gene (rs2854744) is associated with significantly lower IGFBP-3 levels in multiple population studies. Low IGFBP-3 means faster IGF-1 clearance, shortening the active window after each GH pulse. For these users, splitting the same total peptide dose across more administrations per day may better sustain IGF-1 in the effective range.
What your blood IGF-1 test tells you (and what it misses)
Standard IGF-1 blood tests measure total circulating IGF-1. They are useful. A low IGF-1 after four weeks on ipamorelin or CJC-1295 at standard doses is a clear signal of either GHSR bottleneck (the peptide cannot trigger GH release), fl/fl GHR status (the GH-to-IGF1 conversion is inefficient), or STAT5B insufficiency.
The test misses the IGF1R and IGFBP-3 picture entirely. You can have normal-to-high circulating IGF-1 and still see blunted tissue effects if your IGF1R variant is reducing receptor sensitivity at the cell level, or if low IGFBP-3 is clearing IGF-1 before it reaches target tissues. This explains why some users report feeling little from MK-677 despite bloodwork showing their IGF-1 climbed from 150 to 280 ng/mL. Their liver responded. Their cells did not.
| Gene | Variant That Boosts Response | Variant That Limits Response | What It Affects | Practical Fix for Low-Response Variant |
|---|---|---|---|---|
| GHSR | Full-function receptor | Loss-of-function variants | Whether ghrelin-mimetics can trigger GH release | Switch to CJC-1295 (GHRH receptor, not GHSR) |
| GHR (Exon 3) | d3/d3 deletion | fl/fl full-length | IGF-1 production per GH pulse (up to 56% difference) | Increase dosing frequency, not per-dose amount |
| IGF1R (rs2229765) | Arg/Arg (G/G) | His/His (A/A) | Cell-level sensitivity to circulating IGF-1 | Bloodwork alone will not identify this; use genetic testing |
| IGFBP3 (rs2854744) | A/A (high IGFBP-3) | C/C (low IGFBP-3) | IGF-1 half-life and active window length | Split dose across more daily administrations |
If growth peptides are working better than expected, monitor your IGF-1 levels
d3/d3 carriers and those with efficient GHSR function can push IGF-1 into ranges above 350 to 400 ng/mL on doses designed for the population average. That sounds like a win. But there is context worth knowing.
The EPIC-Heidelberg study, a prospective cohort of 7,461 participants followed for 17.5 years and published in the Journal of Clinical Endocrinology and Metabolism in 2023, found that each doubling of circulating IGF-1 was associated with a 25% higher breast cancer incidence rate and a 31% higher prostate cancer incidence rate. The study tracked naturally occurring IGF-1 variation, not secretagogue use, so it does not directly address growth peptide protocols. But it is a reason to monitor bloodwork rather than dose by feel. For more on how receptor downregulation interacts with extended high-IGF-1 exposure, see our guide on GH receptor reset timelines after a peptide cycle.
High-responders benefit from starting lower than standard dosing and adjusting based on bloodwork. Running 150 mcg of ipamorelin instead of 250 to 300 mcg, then measuring IGF-1 at week four, gives you a baseline for your response tier before committing to a full 8 to 12 week cycle.
Share of IGF-1 response variation explained by 38 genetic variants in a 2025 study (Journal of Pediatric Endocrinology and Metabolism) where 132 subjects received identical growth hormone doses. The genetic signal dwarfs dose, timing, and lifestyle variables.
How to identify your bottleneck before changing your protocol
The practical question is which layer is limiting you. The fastest method is a blood test at baseline and at week four of a standard protocol. Run ipamorelin at 200 mcg twice daily. If your IGF-1 shifts less than 50 ng/mL, you have either a GHSR bottleneck (common: switch to CJC-1295 and retest), an fl/fl GHR issue (try three-times-daily dosing), or STAT5B insufficiency (rare but detectable by genetic panel).
If your IGF-1 shifts by 80 to 150 ng/mL but you feel little effect, the problem is likely at the IGF1R level or with rapid IGFBP-3 clearance. Neither shows in blood IGF-1 numbers alone. Genetic testing identifies which variant is responsible and points to the protocol adjustment that actually addresses the root cause. For context on how growth peptides compare at the mechanistic level, see our comparison of ipamorelin vs CJC-1295 and the ipamorelin peptide guide.
Consumer DNA tests (23andMe, AncestryDNA) cover the GHR Exon 3 deletion and IGFBP3 rs2854744 in their raw data files. Raw data uploads to our platform return GHR, IGF1R, GHSR, and STAT5B status alongside the full growth peptide response panel. For the broader framework of using DNA to prioritize which peptides to try first, see our DNA-first peptide decision framework.
The verdict: If growth peptides are not working the way you expected, the protocol is rarely the problem. The genetics almost always are. A 2025 study traced 95.7% of IGF-1 response variation to genetic factors. Three bottlenecks cover the most common failure modes: GHSR variants (the trigger), GHR genotype (the conversion), and IGF1R variants (the cell response). Identifying which one applies to you takes a blood test or a DNA panel, not another dose adjustment. Order a kit to map your full growth peptide response genetics, or upload your existing DNA data for results within 48 hours.
Your DNA shapes how you respond to every peptide in this report.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Why do two people on the same ipamorelin dose get completely different IGF-1 results?
The most common reasons are GHR genotype, GHSR function, and IGF1R sensitivity. About 20% of people carry two full-length GHR copies (fl/fl), which produces a weaker IGF-1 response per GH pulse. A separate group carries loss-of-function GHSR variants, meaning ipamorelin cannot effectively trigger GH release in the first place. Together, two key genetic variables explain 43% of the variation in IGF-1 response to the same growth hormone stimulus.
What is the GHR Exon 3 deletion and how does it affect ipamorelin results?
The GHR Exon 3 deletion is a naturally occurring variant in the growth hormone receptor gene that produces a slightly shorter receptor protein (d3-GHR) with roughly 30% more efficient signaling. d3-GHR carriers show about 56% higher IGF-1 elevation in response to the same GH stimulus compared to individuals with two full-length GHR copies (fl/fl). About 80% of people carry at least one copy of the deletion. The ~20% who are fl/fl are the most likely to feel that ipamorelin is underperfoming at standard doses.
What is a GHSR loss-of-function variant and how does it affect ghrelin-mimetic peptides?
GHSR is the ghrelin receptor, which is the protein that ipamorelin, MK-677, GHRP-6, and GHRP-2 bind to in order to trigger GH release. Loss-of-function GHSR variants reduce or eliminate the receptor's response to ghrelin-mimetics, blocking the first step in the cascade. People with these variants often see little improvement regardless of dose. CJC-1295 works through a different receptor (GHRH receptor) and is unaffected by GHSR variants, making it the better option for this group.
My IGF-1 bloodwork looks fine but I barely feel growth peptide effects. What is happening?
Normal or elevated blood IGF-1 with minimal felt effect usually points to a downstream issue: either an IGF1R variant (rs2229765 His/His) that reduces how well your cells respond to circulating IGF-1, or a low IGFBP-3 variant (rs2854744 C/C) that clears IGF-1 from the bloodstream faster than average. Standard blood tests only measure total IGF-1 production. They do not reveal how efficiently that IGF-1 is binding at the tissue level. Genetic testing is the most direct way to identify which issue applies.
Should I increase my ipamorelin dose if I am a low responder?
Dose escalation is usually the wrong fix for fl/fl GHR carriers. The bottleneck is at the receptor level, so more secretagogue generates more GH but that GH still hits a less efficient receptor. Higher dosing frequency (three times daily instead of two) is more effective because it increases the number of GH pulses over 24 hours. For GHSR-variant carriers, no dose of ipamorelin will fully compensate. Switching to CJC-1295, which works through a different receptor pathway, is the more logical change.
How do I find out if I have the d3-GHR deletion or GHSR variants?
Consumer DNA tests (23andMe, AncestryDNA) include the GHR Exon 3 deletion and IGFBP3 rs2854744 in their raw data. You can upload that raw data to our platform for a full growth peptide genetics report covering GHR, GHSR, IGF1R, and STAT5B. If you do not have prior DNA data, our saliva kit provides the same analysis. A four-week bloodwork protocol (baseline IGF-1 plus week-four retest on ipamorelin 200 mcg twice daily) can also indicate which tier you fall into, though it does not identify the specific variant.
Does GHR genotype affect cancer risk from elevated IGF-1?
The connection is indirect but worth knowing. A 2023 prospective study (EPIC-Heidelberg) found that naturally higher IGF-1 levels in the general population were associated with modestly elevated breast and prostate cancer risk. That study did not examine secretagogue users specifically. d3/d3 carriers who drive IGF-1 to the high end of normal on standard peptide doses should monitor levels with quarterly bloodwork and consider starting lower than population dosing guides suggest, adjusting upward based on their actual bloodwork response.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.